/ New England Journal of Medicine
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups.
N Engl J Med. 2020 Aug 6;383(6):546-557.
doi: 10.1056/NEJMoa1917246. PMID: 32757523
An international research group led by DKF research group leader Prof. Ludwig Kappos (Neurology/USB) and Prof. Stephen Hauser (Neurology/UCSF) demonstrated the superior efficacy of Ofatumumab in two Phase III studies in patients with relapsing-remitting multiple sclerosis. This compared to Teriflunomide, a commonly prescribed oral treatment for MS. Ofatumumab is the first fully human monoclonal antibody to B cells that MS patients can inject themselves subcutaneously.